What are the six national patent anti-recurrence diagnosis and treatment systems of AS?
Because the six national patent anti-recurrence diagnosis and treatment systems pay attention to both the symptoms and the root causes, it is the key factor that leads to the deterioration of drug efficacy and the difficulty in controlling the disease to directly attack the pathological core of ankylosing spondylitis, that is, "the drug nutrition caused by microcirculation disorder cannot enter and the metabolites come out". At the same time, the imbalance of autoimmune disorder leads to disease recurrence. Therefore, this system depends on six national patented technologies. On the one hand, it relieves local microcirculation obstacles, opens up the supply channels of drug nutrition, and allows "drug nutrition to enter". The core premise is that "metabolites can get out", so as to improve the drug effect, block the development of the disease, protect the spine from deformation, destruction and disability, and combine local anti-inflammation, bone repair and minimally invasive release to eliminate pain, restore the motor function of spinal joints and correct hunchback deformity. On the other hand, by adjusting the systemic immune balance, maintaining the long-term mechanism of local effective treatment, establishing self-resistance and anti-recurrence ability, and improving the quality of life. It is of great significance to patients with early, middle and late ankylosis.
Main contents of AS six national patents anti-recurrence diagnosis and treatment system
The diagnosis and treatment system includes six national patent authentication technologies, such as eliminating microcirculation disturbance, diminishing inflammation and relieving pain, releasing adhesion, repairing bones, regulating immunity and preventing recurrence, which comprehensively solves the problems of patients with ankylosing spondylitis, such as poor curative effect, uncontrollable illness, limited pain, hunchback deformity, repeated illness, abnormal indexes and drug dependence.
Advantages of six national patent anti-recurrence diagnosis and treatment systems
1, local combined whole-body standardized diagnosis and treatment system 10 upgrade results: The anti-recurrence diagnosis and treatment system of six national patents AS was formerly known as "local combined whole-body standardized diagnosis and treatment system", which has been applied in clinical practice for 10 years, and achieved remarkable results with an effective rate of 92% and a clinical rehabilitation rate of 82% in the early and middle stages. The core technology has been optimized in this technology.
2. Six China National Intellectual Property Administration certification protection technologies: six core patented technologies, each of which has been strictly examined and approved by China National Intellectual Property Administration, and the effectiveness, safety and qualification of medical units have been protected by national certification, fully protecting the rights and interests of patients;
3. The comprehensive system breaks through the bottleneck and recurrence of traditional drug treatment: it is not a single drug or instrument treatment, but a comprehensive system of one-stop treatment, with the core premise of relieving microcirculation disorder, realizing "drug nutrition goes in and metabolites come out", thus improving the therapeutic effect of anti-inflammatory and bone repair technology, realizing the relief of symptoms, establishing a virtuous circle, restoring the function of self-metabolism and inflammation, adjusting immune balance, and reducing lifelong drug dependence and disease recurrence;
4. The dean and experts of ankylosing diseases have rich experience in independent research and development: the dean and experts of ankylosing diseases independently research and develop patented technology with many years of academic and clinical practice, have mature and rich clinical experience, are good at choosing the best scheme according to the patient's condition, and get better results with less cost.
Zhengzhou Jingke Ankylosing Hospital is a key hospital for ankylosing spondylitis in Central China, a research and diagnosis center for chronic diseases in China and the United States, and an international joint diagnosis and treatment center for rheumatism and immunity. It is also the founding hospital of six national patent anti-recurrence diagnosis and treatment systems. The hospital is led by three deans, and experts from the Beijing-Shanghai-Henan Ankylosing Spondylitis Medical Consultation Center collaborate to develop a one-stop systematic diagnosis and treatment plan to fully ensure that every ankylosing spondylitis patient can receive accurate and efficient diagnosis and treatment.